Skip to main content

Table 1 Baseline characteristics of 222 myeloma patients

From: Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma

  No. of patients (%) P value*
Non-BSI
(n = 196)
BSI
(n = 26)
Gender      
 Male 141 (72) 17 (65) 0.492
 Female 55 (28) 9 (35)  
Age ≥ 65 y/o 127 (65) 19 (73) 0.402
Myeloma subgroup
 IgG 95 (48) 13 (50) 0.741
 IgA 63 (32) 9 (35)  
 Light chain disease 29 (15) 4 (15)  
 Other typesa 9 (5) 0 (0)  
Immunoglobulin status
 Severe Ig deficiencyb 177 (90) 23 (88) 0.767
 Others 19 (10) 3 (12)  
ALC count ≥ 1000 (/ul) 138 (70) 17 (65) 0.612
ISS Stage
 I 37 (19) 1 (4)  
 II 64 (33) 5 (19)  
 III 95 (48) 20 (77) 0.019
ECOG PS >2 59 (30) 17 (65) <.001
Hb < 10 (g/dL) 108 (55) 21 (81) 0.015
Ca > 12.0 (mg/dL) 14 (7) 5 (19) (58) 0.038
Cr ≥ 2.0 (mg/dL) 55 (28) 15   0.002
Induction chemotherapy
 VAD-based 57 (29) 13 (50)  
 MP-based 83 (42) 7 (27) 0.064
 Othersc 30 (15) 1 (4)  
 No 26 (13) 5 (19)  
  1. Abbreviations: BSI Blood stream infection, IgG Immunoglobulin G, IgA Immunoglobulin A, Ig Immunoglobulin, ALC Absolute lymphocyte count, ISS International Staging System, ECOG PS Eastern Cooperative Oncology Group Performance Status, Hb Hemoglobin, Ca Calcium, Cr Creatinine, VAD Vincristine/doxorubicin/dexamethasone, MP Melphalan/prednisolone
  2. aOther types include solitary plasmacytomas and plasma cell leukemia
  3. bSevere Ig deficiency is defined as both of the non-myeloma immunoglobulin levels less than one-fourth of lower normal limit
  4. cIncluding newer regimens such as thalidomide/dexamethasone (TD), bortezomib/cyclophosphamide/dexamethasone (BCD), bortezomib/dexamethasone (BD), cyclophosphamide/thalidomide/dexamethasone (CTD), and bortezomib/cyclophosphamide/dexamethasone (BTD)
  5. *Statistics analysis is used Chi-square or Fisher exact test